Ischemia  >>  rivaroxaban  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rivaroxaban / Generic mfg.
ROCKET AF, NCT00403767 / 2006-004595-13: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Checkmark ROCKET AF
Oct 2013 - Oct 2013: ROCKET AF
Checkmark ROCKET AF: Efficacy of rivaroxaban compared with warfarin
Jun 2013 - Jun 2013: ROCKET AF: Efficacy of rivaroxaban compared with warfarin
Completed
3
14269
Europe, Canada, US, RoW
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Bayer
Atrial Fibrillation, Stroke, Embolism
09/10
09/10
NCT00809965: An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Checkmark AHA 2013 - ATLAS ACS 2-TIMI 51
Nov 2013 - Nov 2013: AHA 2013 - ATLAS ACS 2-TIMI 51
Checkmark ATLAS ACS TIMI 51 study
May 2013 - May 2013: ATLAS ACS TIMI 51 study
Checkmark ATLAS ACS 2-TIMI 51
More
Completed
3
15526
Europe, Canada, Japan, US, RoW
Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Bayer
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
09/11
09/11
X-VERT, NCT01674647 / 2011-002234-39: Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Completed
3
1504
US, Canada, Europe, RoW
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Bayer, Janssen Research & Development, LLC
Atrial Fibrillation
01/14
01/14
CLOSE, NCT00562289 / 2011-000110-19: Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence

Completed
3
664
Europe
aspirin, clopidogrel, combination aspirin-dipyridamole, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure, Each device for PFO closure must have the CE mark, and be approved by the Interventional Cardiology Committee
Assistance Publique - Hôpitaux de Paris
Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
12/16
12/16
NAVIGATE ESUS, NCT02313909 / 2013-000768-27: Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Terminated
3
7213
Europe, Canada, Japan, US, RoW
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
Bayer, Janssen Research & Development, LLC, Population Health Research Institute
Stroke
02/18
02/18
NCT01877915 / 2013-000046-19: A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Checkmark Efficacy and safety data from COMMANDER HF study
Oct 2018 - Oct 2018: Efficacy and safety data from COMMANDER HF study
Checkmark COMMANDER HF data in patients with heart failure and coronary artery disease at ESC 2018 [screenshot]
Aug 2018 - Aug 2018: COMMANDER HF data in patients with heart failure and coronary artery disease at ESC 2018 [screenshot]
Completed
3
5081
Europe, Canada, Japan, US, RoW
Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease
Janssen Research & Development, LLC, Bayer
Heart Failure, Coronary Artery Disease
04/18
04/18

Download Options